Navigation Links
Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010
Date:7/29/2010

AUSTIN, Texas,  July 29 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, will host a web cast and conference call to give a company update following issuance of Q2 financial results on Monday, August 16, 2010.

Conference Call Information

To access the live conference call via phone, dial (800) 757 8521 from the United States and Canada or +1 212 231 2901 internationally. The conference ID is 21477823.  Please dial-in approximately ten minutes prior to the start of the call. You may also access the live and subsequently archived web cast of the conference call from the Investor Relations section of the Company's website at http://www.vermillion.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

A telephone replay of the call will be available beginning approximately one hour after the call through August 31, 2010, and may be accessed by dialing (800) 633 8625 from the United States and Canada or +1 402 977 9141 internationally. The replay passcode is 21477823.  An archived replay of the web cast will be available until the next quarterly call.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at www.vermillion.com.

Forward Looking Statements

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize ovarian cancer or OVA1™ diagnostics products in 2010 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to develop, and commercialize diagnostic products based on findings from its disease association studies; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of market acceptance of its OVA1™ diagnostic test or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.   In addition, any financial information presented in this press release is unaudited and subject to adjustment following Vermillion's internal review and quarterly processes as well as annual audit.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Announces Relocation of Corporate Offices to Austin, Texas
2. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
3. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
4. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
5. Vermillion Announces the Reappointment of Officers and Confirmation of Director
6. Vermillion Announces $43.05 Million Private Placement of Common Stock
7. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
8. Vermillion Files Plan of Reorganization
9. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
10. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
11. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 ML Capital Group, Inc. (USOTC: ... Colorado Highlife Tours , a Colorado -based ... with Puration, Inc. (USOTC: PURA) to enter Colorado,s ... The Colorado Highlife Tours acquisition announced today is intended to accelerate ... ...
(Date:2/23/2017)... and VANCOUVER, British Columbia , ... OGXI ) today announced its year end 2016 ... In January 2017, OncoGenex, and Achieve Life Science, Inc., ... have entered into a definitive merger agreement under which ... completion of the proposed merger, Achieve,s stockholders are expected ...
(Date:2/23/2017)... 22, 2017 Medical Imaging ... is performed to reveal the internal structures hidden by ... medical condition. It plays a vital role not only ... it is taken into consideration during the follow-up of ... SPECT/PET, ultrasound, CT, and MRI. For the diagnosis and ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 23, 2017 , ... On April 13, 2017, The ... “Doping in Sport: How the Culture Might Change,” in conjunction with Pepperdine ... will be held at Pepperdine University in Malibu, California. , Sir Philip Craven, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an exciting, new, interactive publication where generations converge and explore the world from ... their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation , a ... franchising throughout the U.S. starting this spring. Current Meditation focuses on “meditation for ... mainstream. Current Meditation will be the first meditation concept in the U.S. offering ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... CALNOC, ... FACP, FACMPE, FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – ... the chairman and CEO of the Virginia Mason Health System in Seattle since 2000. ...
Breaking Medicine News(10 mins):